RxDoctor Payments Data

Nor Darwish, MD

Family Medicine · Staten Island, NYNPI 1487031274

Payments from drug & device makers

$3,578in general payments, 2019–2025

Across 117 payments — averaging $30.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$905
  • Pfizer$396
  • Amgen$303
  • AstraZeneca$302
  • Intra-sana Laboratories$298
  • Lilly USA, LLC$232
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,578 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$11,251
Medicare patients
36
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lactulose31$84,096
OzempicSemaglutide55$74,708
Albendazole12$60,200
Zileuton ErZileuton22$51,039
LinzessLinaclotide46$43,094
MounjaroTirzepatide29$42,026
JanuviaSitagliptin Phosphate35$40,030
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate18$32,835
JardianceEmpagliflozin24$32,352
Diclofenac Sodium76$31,809
VascepaIcosapent Ethyl30$22,875
Diclofenac Potassium11$22,768
FarxigaDapagliflozin Propanediol22$19,654
MeloxicamMeloxicam, Submicronized14$13,898
Janumet XrSitagliptin Phos/Metformin Hcl17$11,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$74,70855 claims
MerckJanuvia, Janumet Xr$31$51,07252 claims
AbbVieLinzess$148$43,09446 claims
Lilly USA, LLCMounjaro$232$42,02629 claims
AstraZenecaFarxiga, Symbicort$302$22,16533 claims
PfizerEliquis$396$10,52411 claims
Kowa Pharmaceuticals America, Inc.Livalo$14$4,26515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →